Cambridge City Publishers
  • info.clinical@cardiologycasereportsjournal.org
  • CB1 OBG, Cambridge City, UK
  • Submit Manuscript

Article Details

Case Report
Volume 3, Issue 3 (August Issue)

Levosimendan as an Adjunctive Treatment to Sinus Rhythm Restoration in Arrhythmia-Induced Cardiomyopathy

Rebeca Munoz-Rodriguez*

University Hospital of the Canary Islands, San Cristobal de La Laguna, Tenerife, Spain

*Corresponding author: Rebeca Munoz-Rodriguez, University Hospital of the Canary Islands, San Cristobal de La Laguna, Tenerife, Spain.

Received: July 28, 2023; Accepted: August 10, 2023; Published: August 25, 2023

Citation: Munoz-Rodriguez R. Levosimendan as an Adjunctive Treatment to Sinus Rhythm Restoration in Arrhythmia-Induced Cardiomyopathy. Case Rep Clin Cardiol J. 2023; 3(3): 135.

Levosimendan as an Adjunctive Treatment to Sinus Rhythm Restoration in Arrhythmia-Induced Cardiomyopathy
Abstract

Arrhythmia-induced cardiomyopathy is characterized by ventricular remodeling and impaired contractile function due to persistent or paroxysmal atrial or ventricular arrhythmias, leading to increased heart rate. This condition is reversible upon restoring sinus rhythm. Levosimendan, a drug that enhances contractility without raising myocardial oxygen consumption, shows promise in augmenting ventricular function recovery when combined with sinus rhythm restoration. We present the case of a 68-year-old with atrial flutter who developed LV performance deterioration due to tachyarrhythmia, in the form of arrhythmia-induced cardiomyopathy, causing acute heart failure. Levosimendan, adjuntive to sinus rythm restoration, enhanced myocardial recovery.